Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cariogenic microorganisms refer to a complex community of bacteria, most notably Streptococcus mutans, Streptococcus sobrinus, and various Lactobacillus species, that are the primary drivers of dental caries (Lemos et al., 2019, Microbiol Spectr). These organisms are characterized by their ability to ferment dietary sugars into organic acids, such as lactic acid, which significantly lowers the pH within the oral environment and leads to the demineralization of tooth enamel (StatPearls, 2023). A defining feature of these microbes is their capacity to produce extracellular polysaccharides (glucans) that facilitate the formation of a resilient biofilm, or dental plaque, which protects the bacteria from host defenses and antimicrobial agents (NCBI, PMC2830005). Therapeutic strategies often involve the use of broad-spectrum antimicrobials like chlorhexidine or metabolic inhibitors like fluoride to reduce microbial load and acid output. However, because this target represents a collective of diverse species rather than a single molecular entity, it is considered a broad pathological category in dental medicine rather than a specific pharmacological target (NIH, 2021).
Drugs targeting cariogenic microorganisms work through several pathways: fluoride inhibits the bacterial enzyme enolase and decreases acid tolerance; chlorhexidine and cetylpyridinium chloride act as cationic surfactants that disrupt the bacterial cell membrane; and xylitol acts as a non-fermentable sugar alcohol that causes a 'futile cycle' in bacteria like S. mutans, inhibiting their growth and acid production (Marquis, 1995, Can J Microbiol; Jones, 1997, J Dent).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cariogenic microorganisms.